GlaxoSmithKline has in-licensed Janssen’s anti-IL-33R monoclonal antibody for severe asthma. The British drugmaker is paying €208m up front for the mAb.
In view of the Brexit, research academies across Britain are calling for a bold commitment from the government. The Royal Society President urges the UK government to underwrite the research of British scientists applying for EU funding.
JANUS® Automation Workstations deliver real-time and future adaptability in throughput, capacity, and dynamic volume range from 0.5 ?l to 5000 ?l for consistent and reproducible sample preparation
Swedish rare disease expert Wilson Therapeutics AB has appointed global regulatory executive Rick Lilley as Chief Regulatory Officer.
Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.
Eduardo Bravo takes over as President of the Board of Directors of European Biopharmaceutical Enterprises (EBE). Bravo is CEO of Belgian stem cell-based drug developer TiGenix NV.
Europe’s first gene therapy company has floated on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.
Merck’s advanced water purification system with new high-throughput line delivers up to 9,000 liters of pure water daily with real-time monitoring and ensures constant water quality with low and predictable running costs.
When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.
Uwe Meya is taking over as Chief Medical Officer at Barcelona-based orphan drug developer Minoryx Therapeutics. Meya will advance the clinical development of Minoryx’ lead candidate MIN-102 for adrenoleukodystrophy.